
Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbHOur Cardiovascular Commitment

“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”
We are the pioneer behind leading pharmaceuticals such as
- Adrenalin (an adrenal cortex hormone agent that became the first blockbuster medicine of the 20th century)
- Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)
Our current cardiovascular portfolio includes products for
- Atrial fibrillation
- Hypertension
- Thrombotic disorders
*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries